The present study identified that the DAPK1 gene is significantly methylated (including possible hydroxymethylation) in CML patients and this is correlated with mutations that result in resistance to imatinib. Here, DAPK1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.